<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02930018</url>
  </required_header>
  <id_info>
    <org_study_id>NA-1-007</org_study_id>
    <nct_id>NCT02930018</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of NA-1 in Subjects Undergoing Endovascular Thrombectomy for Stroke (ESCAPE-NA1)</brief_title>
  <acronym>ESCAPE-NA1</acronym>
  <official_title>A Multicentre, Randomized, Double-blinded, Placebo-controlled, Parallel Group, Single-dose Design to Determine the Efficacy and Safety of Intravenous NA-1 in Subjects With Acute Ischemic Stroke Undergoing Endovascular Thrombectomy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NoNO Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Calgary</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>NoNO Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The ESCAPE-NA-1 study is designed to determine the safety and efficacy of the
      neuroprotectant, NA-1, in reducing global disability in subjects with major acute ischemic
      stroke (AIS) with a small established infarct core and with good collateral circulation who
      are selected for endovascular revascularization.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Trial Objectives:

      The primary objective is to determine the efficacy of the neuroprotectant, NA-1, in reducing
      global disability in subjects with major acute ischemic stroke (AIS) with a small established
      infarct core and with good collateral circulation selected for rapid endovascular
      revascularization.

      The secondary objectives are to determine the efficacy of NA-1 in:

        -  Reducing functional dependence

        -  Improving neurological outcome

        -  Improving activities of daily living

        -  Reducing mortality rate The leading safety objectives are to determine the effect of
           administering a dose of 2.6 mg/kg intravenous (IV) infusion of NA-1 to subject with
           acute stroke who are selected for endovascular revascularization on serious adverse
           events (SAEs) and 90-day mortality.

      Trial Design:

      This study is a Phase 3, randomized, multicentre, blinded, placebo-controlled, parallel
      group, single-dose design. Subjects harboring an acute ischemic stroke and who are selected
      for endovascular revascularization in accordance with local institutional practices and who
      harbor a small established infarct core and with good collateral circulation will be given a
      single, 2.6 mg/kg intravenous dose of NA-1 or placebo as soon as they are deemed to have met
      the enrollment criteria and started within 30 minutes of randomization. The randomization
      will be by stochastic minimization to balance baseline factors.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 1, 2017</start_date>
  <completion_date type="Anticipated">April 2020</completion_date>
  <primary_completion_date type="Anticipated">April 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Modified Rankin Score (mRS)</measure>
    <time_frame>90 Days</time_frame>
    <description>Overall proportion of subjects experiencing a favorable functional outcome 90 days post-randomization, defined as 0 to 2 on the mRS</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>mRS Shift Analysis</measure>
    <time_frame>90 Days or the last rating</time_frame>
    <description>Shift of one or more categories to reduced functional dependence analyzed across the whole distribution of scores on the mRS at Day 90 or the last rating.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>NIHSS</measure>
    <time_frame>90 Days or the last rating</time_frame>
    <description>Proportion of subjects with good neurological outcome, as defined by a score of 0-2 on the NIHSS at Day 90 or the last rating.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Barthel Index</measure>
    <time_frame>90 Days or the last rating</time_frame>
    <description>Proportion of subjects with functional independence in activities of daily living, as defined by a score of ≥ 95 on the BI at Day 90 or the last rating.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality Rate</measure>
    <time_frame>90 Days</time_frame>
    <description>A reduction in mortality rate, as defined by event rate (%) for mortality over the 90-day study period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Functional Independence based on mRS</measure>
    <time_frame>90 Days or the last rating</time_frame>
    <description>Proportion of subjects with functional independence, as defined by a score of 0-1 on the mRS at Day 90 or the last rating.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>EQ-5D-5L</measure>
    <time_frame>90 Days or the last rating</time_frame>
    <description>Health-related quality of life, as measured by the EQ-5D-5L at Day 90 or the last rating.</description>
  </other_outcome>
  <other_outcome>
    <measure>Stroke Volume</measure>
    <time_frame>24 hour follow up</time_frame>
    <description>Volume of stroke as measured by MRI. If NCCT was done instead of MRI, Volume of stroke will be derived from hypodense areas.</description>
  </other_outcome>
  <other_outcome>
    <measure>Test of language function</measure>
    <time_frame>90 Days</time_frame>
    <description>Cognitive outcome - The 15-item Boston Naming Test (BNT15)</description>
  </other_outcome>
  <other_outcome>
    <measure>Test of hemi-spatial neglect</measure>
    <time_frame>90 Days</time_frame>
    <description>Cognitive Outcome - Sunnybrook hemi-spatial neglect procedure (SNAP)</description>
  </other_outcome>
  <other_outcome>
    <measure>Global test of cognitive function. Scale from 0 to 30 points.</measure>
    <time_frame>90 Days</time_frame>
    <description>Cognitive outcome - The Montreal Cognitive Assessment (MoCA)</description>
  </other_outcome>
  <other_outcome>
    <measure>Functional outcome based on mRS</measure>
    <time_frame>30 days</time_frame>
    <description>The proportion of subjects experiencing a favorable functional outcome 30 days post-randomization, defined as 0 to 2 on the mRS.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">1120</enrollment>
  <condition>Stroke, Acute</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Drug vehicle only</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NA-1, 2.6 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single intravenous infusion of NA-1 over 10 ± 1 minutes</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NA-1, 2.6 mg/kg</intervention_name>
    <description>Single intravenous infusion of NA-1 over 10 ± 1 minutes</description>
    <arm_group_label>NA-1, 2.6 mg/kg</arm_group_label>
    <other_name>Tat-NR2B9c</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo Comparator: Placebo</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Drug vehicle only</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Acute ischemic stroke (AIS) for immediate endovascular treatment

          2. Age 18 or greater.

          3. Onset (last-seen-well) time to randomization time within 12 hours.

          4. Disabling stroke defined as a baseline National Institutes of Health Stroke Score
             (NIHSS) &gt; 5 at the time of randomization.

          5. Pre-stroke (24 hours prior to stroke onset) independent functional status in
             activities of daily living with modified Barthel Index (BI) &gt; 90 (95 or 100). Patient
             must be living in their own home, apartment or seniors lodge where no nursing care is
             required.

          6. Confirmed symptomatic intracranial occlusion, based on multiphase or dynamic
             computerized tomographic angiography (CTA), at one or more of the following locations:
             Intracranial carotid T/L, M1 middle cerebral artery (MCA). Functionally, when defining
             the M1 or the M2, the bulk of the MCA territory must be ischemic.

          7. Non-contrast computed tomography (NCCT) and CTA (multiphase or dynamic) for trial
             eligibility performed or repeated at ESCAPE-NA1 stroke centre with endovascular suite
             on-site.

          8. Endovascular treatment with declared first endovascular approach as either stent
             retriever or aspiration device, and intended to be initiated (arterial access) within
             60 minutes of baseline/qualifying NCCT and to first recanalization of 90 minutes.
             Study drug intended to be administered within 60 minutes of the baseline/qualifying
             NCCT.

          9. Signed informed consent from subject or legally authorized representative.

        Exclusion Criteria:

          1. Evidence of a large core of established infarction defined as ASPECTS 0-4.

          2. Evidence of absence of collateral circulation on CTA (Collateral score of 0 or 1).

          3. Intent to use any endovascular device other than a stent retriever or clot aspiration
             device or intra-arterial medications as the initial thrombectomy approach.

          4. Intent to use any intravenous thrombolytic other than alteplase if intravenous
             thrombolysis is planned.

          5. No femoral pulses, very difficult endovascular access or extreme tortuosity of great
             vessels that is predicted to result in an inability to deliver timely endovascular
             therapy. Direct common carotid or radial/brachial/axillary access is permissible.

          6. Estimated or known weight &gt; 120 kg or &lt; 45 kg.

          7. Pregnancy; if a woman is of childbearing potential a urine or serum beta human
             chorionic gonadotropin (β-hCG) test is positive, or breastfeeding.

          8. Severe contrast allergy or absolute contraindication to iodinated contrast preventing
             endovascular intervention.

          9. Clinical history, past imaging or clinical judgment suggests that the intracranial
             occlusion is chronic or there is suspected intracranial dissection such that there is
             a predicted lack of success with endovascular intervention.

         10. Prior enrolment in the ESCAPE-NA1 trial or prior receipt of NA-1 for any reason.

         11. Severe known renal impairment defined as requiring dialysis (hemo- or peritoneal) or
             if known a creatinine clearance &lt; 29 mL/min.

         12. Patient has a severe or fatal comorbid illness that will prevent improvement or
             follow-up.

         13. Patient cannot complete follow-up treatment due to co-morbid non-fatal illness or they
             are known to be a visitor to the city or any other known reason for which follow-up
             would be impossible (e.g. incarcerated in a federal prison).

         14. Participation in another clinical trial investigating a drug, medical device, or a
             medical procedure in the 30 days preceding study inclusion.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael D Hill, MD MSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Calgary</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Michael Tymianski, MD PhD</last_name>
    <phone>416-603-5899</phone>
    <email>mtymianski@nonoinc.ca</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Kathy Heard, MSc</last_name>
    <phone>416-603-5481</phone>
    <email>kheard@nonoinc.ca</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Ronald Reagan UCLA Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sidney Starkman, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>California Pacific Medical Center - Davies Campus</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joey English, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Providence Little Company of Mary Medical Center Torrance</name>
      <address>
        <city>Torrance</city>
        <state>California</state>
        <zip>90503</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jason Tarpley, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Swedish Medical Center</name>
      <address>
        <city>Englewood</city>
        <state>Colorado</state>
        <zip>80110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Donald Frei, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Yale New Haven Hospital</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06510</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Joseph Schindler, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Baptist Health Medical Center</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32207</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eric Sauvageau, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Grady Memorial Hospital</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30303</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Raul Noguiera, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>WellStar Health Systems</name>
      <address>
        <city>Marietta</city>
        <state>Georgia</state>
        <zip>30060</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Rishi Gupta, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Rush University Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>George Lopez</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Massachusetts Medical School</name>
      <address>
        <city>Worcester</city>
        <state>Massachusetts</state>
        <zip>01655</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Rex, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Saint Luke's Hospital of Kansas City</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64111</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Coleman Martin, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>NYU Lutheran Medical Center</name>
      <address>
        <city>Brooklyn</city>
        <state>New York</state>
        <zip>11220</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Turkel-Parrella, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Gates Vascular Institute</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Adnan Siddiqui, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Novant Health Forsyth Medical Center</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27103</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Don Heck</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Riverside Radiology</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43214</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ronald Budzik, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Abington Memorial Hospital</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19001</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hana Choe, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>UPMC Presbyterian</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ashutosh Jadhav, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Rhode Island Hospital</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02903</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ryan McTaggart</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Chattanooga Center for Neurologic Research</name>
      <address>
        <city>Chattanooga</city>
        <state>Tennessee</state>
        <zip>37403</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ruchir Shah</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Swedish Medical Center- Cherry Hill Campus</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98122</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cameron McDougall, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Royal Adelaide Hospital</name>
      <address>
        <city>Adelaide</city>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Timothy Kleinig, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Royal Melbourne Hospital</name>
      <address>
        <city>Parkville</city>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bruce Campbell, MD</last_name>
      <email>Bruce.Campbell@mh.org.au</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Calgary - Foothills Medical Centre</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T2N2T9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrew M Demchuk, MD</last_name>
      <email>ademchuk@ucalgary.ca</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Alberta Hospital</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6G 2B7</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kenneth Butcher, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Vancouver Stroke Program Research Office/ Vancouver General Hosptial</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V5Z 1M9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thalia Field, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Queen Elizabeth II Health Science Centre</name>
      <address>
        <city>Halifax</city>
        <state>Nova Scotia</state>
        <zip>B3H 3A7</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephen Phillips, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hamilton General Hospital</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8L 2X2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Demetrios Sahlas, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>London Health Sciences Centre- University Hospital</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A 5A5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jennifer Mandzia, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Ottawa Hospital</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1Y 4E9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dar Dowlatshahi, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sunnybrook Health Centre</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M4N 3M5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Richard Swartz, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>St Michael's Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5B 1W8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daniel Selchen, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Health Network - Toronto Western Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5T 2S8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Frank Silver, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHUM Hopital Notre-Dame</name>
      <address>
        <city>Montréal</city>
        <state>Quebec</state>
        <zip>H2L 4M1</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alexandre Poppe, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Montreal Neurological Institute and Hospital</name>
      <address>
        <city>Montréal</city>
        <state>Quebec</state>
        <zip>H3A1A1</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Donatella Tampieri, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU de Quebec- Universite Laval- Hopital de l'Enfant-Jesus</name>
      <address>
        <city>Quebec City</city>
        <state>Quebec</state>
        <zip>G1J 1Z4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marie-Christine Camden, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Royal University Hospital</name>
      <address>
        <city>Saskatoon</city>
        <state>Saskatchewan</state>
        <zip>S7N 0W8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Kelly, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dortmund</name>
      <address>
        <city>Dortmund</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Stefan Rohde</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dresden</name>
      <address>
        <city>Dresden</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Volker Puetz, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Göttingen</name>
      <address>
        <city>Göttingen</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Marios Psychogios, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Hamburg-Eppendorf</name>
      <address>
        <city>Hamburg</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Götz Thomalla, MD</last_name>
      <email>thomalla@uke.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Beaumont Hospital</name>
      <address>
        <city>Dublin</city>
        <country>Ireland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>John Thornton, MD</last_name>
      <email>johnthornton@beaumont.ie</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mater Hospital</name>
      <address>
        <city>Dublin</city>
        <country>Ireland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Seán Murphy, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dongsan Medical Centre</name>
      <address>
        <city>Daegu</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sung-Il Sohn, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Inha University Hospital</name>
      <address>
        <city>Incheon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joung-Ho Rha, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Oh-Young Bang, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Yonsei Univ, Severence</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ji-Hoe Heo, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Skåne University Hospital</name>
      <address>
        <city>Lund</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Johan Wasselius, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Karolinksa Institutet</name>
      <address>
        <city>Stockholm</city>
        <zip>17176</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Staffan Holmin, MD</last_name>
      <email>staffan.holmin@ki.se</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Royal Victoria Hospital</name>
      <address>
        <city>Belfast</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paul Burns, MD</last_name>
      <email>paul.burns@belfasttrust.hscni.net</email>
    </contact>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Canada</country>
    <country>Germany</country>
    <country>Ireland</country>
    <country>Korea, Republic of</country>
    <country>Sweden</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Hill MD, Martin RH, Mikulis D, Wong JH, Silver FL, Terbrugge KG, Milot G, Clark WM, Macdonald RL, Kelly ME, Boulton M, Fleetwood I, McDougall C, Gunnarsson T, Chow M, Lum C, Dodd R, Poublanc J, Krings T, Demchuk AM, Goyal M, Anderson R, Bishop J, Garman D, Tymianski M; ENACT trial investigators. Safety and efficacy of NA-1 in patients with iatrogenic stroke after endovascular aneurysm repair (ENACT): a phase 2, randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2012 Nov;11(11):942-50. doi: 10.1016/S1474-4422(12)70225-9. Epub 2012 Oct 8.</citation>
    <PMID>23051991</PMID>
  </reference>
  <reference>
    <citation>Cook DJ, Teves L, Tymianski M. Treatment of stroke with a PSD-95 inhibitor in the gyrencephalic primate brain. Nature. 2012 Feb 29;483(7388):213-7. doi: 10.1038/nature10841.</citation>
    <PMID>22388811</PMID>
  </reference>
  <reference>
    <citation>Cook DJ, Teves L, Tymianski M. A translational paradigm for the preclinical evaluation of the stroke neuroprotectant Tat-NR2B9c in gyrencephalic nonhuman primates. Sci Transl Med. 2012 Oct 3;4(154):154ra133. doi: 10.1126/scitranslmed.3003824.</citation>
    <PMID>23035045</PMID>
  </reference>
  <reference>
    <citation>Sun HS, Doucette TA, Liu Y, Fang Y, Teves L, Aarts M, Ryan CL, Bernard PB, Lau A, Forder JP, Salter MW, Wang YT, Tasker RA, Tymianski M. Effectiveness of PSD95 inhibitors in permanent and transient focal ischemia in the rat. Stroke. 2008 Sep;39(9):2544-53. doi: 10.1161/STROKEAHA.107.506048. Epub 2008 Jul 10.</citation>
    <PMID>18617669</PMID>
  </reference>
  <reference>
    <citation>Aarts M, Liu Y, Liu L, Besshoh S, Arundine M, Gurd JW, Wang YT, Salter MW, Tymianski M. Treatment of ischemic brain damage by perturbing NMDA receptor- PSD-95 protein interactions. Science. 2002 Oct 25;298(5594):846-50.</citation>
    <PMID>12399596</PMID>
  </reference>
  <reference>
    <citation>Sattler R, Xiong Z, Lu WY, Hafner M, MacDonald JF, Tymianski M. Specific coupling of NMDA receptor activation to nitric oxide neurotoxicity by PSD-95 protein. Science. 1999 Jun 11;284(5421):1845-8.</citation>
    <PMID>10364559</PMID>
  </reference>
  <reference>
    <citation>Goyal M, Demchuk AM, Menon BK, Eesa M, Rempel JL, Thornton J, Roy D, Jovin TG, Willinsky RA, Sapkota BL, Dowlatshahi D, Frei DF, Kamal NR, Montanera WJ, Poppe AY, Ryckborst KJ, Silver FL, Shuaib A, Tampieri D, Williams D, Bang OY, Baxter BW, Burns PA, Choe H, Heo JH, Holmstedt CA, Jankowitz B, Kelly M, Linares G, Mandzia JL, Shankar J, Sohn SI, Swartz RH, Barber PA, Coutts SB, Smith EE, Morrish WF, Weill A, Subramaniam S, Mitha AP, Wong JH, Lowerison MW, Sajobi TT, Hill MD; ESCAPE Trial Investigators. Randomized assessment of rapid endovascular treatment of ischemic stroke. N Engl J Med. 2015 Mar 12;372(11):1019-30. doi: 10.1056/NEJMoa1414905. Epub 2015 Feb 11.</citation>
    <PMID>25671798</PMID>
  </reference>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 6, 2016</study_first_submitted>
  <study_first_submitted_qc>October 7, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 11, 2016</study_first_posted>
  <last_update_submitted>April 27, 2018</last_update_submitted>
  <last_update_submitted_qc>April 27, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 30, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Acute Ischemic Stroke</keyword>
  <keyword>Endovascular Thrombectomy</keyword>
  <keyword>Neuroprotection</keyword>
  <keyword>Tat-NR2B9c</keyword>
  <keyword>NA-1</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stroke</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

